Meeting
2014 ASCO Annual Meeting
Free light chain assay and cytogenetic abnormalities for identification of high-risk smoldering myeloma.
Authors
Jeremy Todd Larsen
Mayo Clinic, Rochester, MN
Jeremy Todd Larsen , Shaji Kumar , Wilson I. Gonsalves , Vinay Gupta , Brandt L. Esplin , Rhett P. Ketterling , William Morice , Robert A. Kyle , Angela Dispenzieri , S. Vincent Rajkumar
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lymphoma and Plasma Cell Disorders
Track
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Sub Track
Multiple Myeloma
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr 8595)
DOI
10.1200/jco.2014.32.15_suppl.8595
Abstract #
8595
Poster Bd #
282
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Evaluating serum-free light chain ratio as a biomarker for multiple myeloma.
First Author: Theresia Akhlaghi
Poster
2022 ASCO Annual Meeting
African American patients with smoldering multiple myeloma may have a lower risk of progression compared to White patients.
First Author: Theresia Akhlaghi
Poster
2017 ASCO Annual Meeting
Risk stratification of smoldering multiple myeloma (SMM): Predictive value of free light chains and group-based trajectory modeling (GBTM).
First Author: Ajai Chari
Poster
2022 ASCO Annual Meeting
Clinical features of patients with multiple myeloma harboring t(4;14) and impact on long-term survival.
First Author: Nisha Joseph